Skip to main content
NVDA-1.19%AAPL+0.67%GOOGL-2.28%MSFT-0.48%AMZN-0.82%TSM-0.83%SPCX-3.86%AVGO-1.13%META+0.20%TSLA-1.97%SKHY+7.05%MU-3.05%BRK-B+0.18%LLY+0.02%JPM+0.34%AMD+3.04%WMT-0.21%V-0.34%XOM+2.24%ASMLa-2.91%JNJ-0.76%INTC+1.69%MA-0.59%0700.HK-1.94%ORCL-0.50%1398.HK+0.79%BAC+0.45%ABBV+0.88%CSCO+0.24%CVX+1.91%COST-0.83%LRCX-1.43%KO-0.92%CAT-0.84%AMAT-0.83%0005.HK-0.78%AP2d-2.69%UNH-1.94%DELL+0.29%HSBA.L-1.34%MS-0.42%PG-2.02%GE-2.83%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX-0.96%HD-1.04%GS-0.75%0939.HK+1.66%NZDJPY-2.62%AUDJPY-1.87%CHFJPY-1.71%NZDCAD-1.45%GBPJPY-1.39%EURJPY-1.38%NZDUSD-1.37%EURNZD+1.28%USDJPY-1.28%GBPNZD+1.24%CADJPY-1.19%NZDCHF-0.95%USDZAR+0.95%USDSEK+0.88%USDNOK+0.87%AUDNZD+0.78%AUDCAD-0.72%EURZAR+0.67%USDTHB+0.61%USDMXN+0.61%AUDUSD-0.61%EURSEK+0.60%GBPZAR+0.59%EURNOK+0.59%AUDSGD-0.54%USDPLN+0.53%AUDDKK-0.52%CADCHF+0.51%EURAUD+0.50%CHFSEK+0.49%CHFNOK+0.48%GBPAUD+0.47%USDCHF+0.45%GBPTRY+0.41%NOKJPY-0.41%NZDSGD-0.38%GBPHKD+0.32%EURCHF+0.32%GBPCHF+0.30%EURHKD-0.30%GBPMXN-0.28%USDDKK+0.28%USDSGD+0.27%EURPLN+0.25%GBPCAD-0.22%EURCAD-0.20%SGDJPY+0.19%EURCNH-0.17%AUDCHF-0.17%USDILS+0.16%CHFSGD-0.12%GBPUSD-0.12%EURUSD-0.12%USDTRY+0.11%USDCNH+0.09%GBPSGD-0.09%USDCAD-0.08%PLNJPY-0.07%NZDMXN-0.06%AUDNOK+0.06%USDCOP-0.04%EURCZK-0.03%EURGBP+0.03%EURSGD-0.01%USDHKD+0.01%EURDKK0.00%XPTUSD-4.86%XAGUSD-4.32%GAGUSD-4.32%HG1-4.09%UKOIL+3.27%USOIL+3.15%COFFEE-2.45%GAUUSD-1.17%XAUUSD-1.17%SUGAR+1.15%COTTON+0.60%XNGUSD-0.29%BTCUSD-1.81%ETHUSD-2.01%USDTUSD-0.02%XRPUSD-2.77%SOLUSD-2.07%TRXUSDT-0.17%ZECUSDT-5.51%DOGEUSD-2.88%XMRUSDT-2.04%LINKUSD-1.08%XLMUSD-2.10%BCHUSDT-8.60%LTCUSD-2.09%UNIUSD-4.73%TONUSD+24.88%HBARUSDT-2.37%SUIUSD-2.75%TAOUSDT-4.55%AAVEUSD-3.25%DOTUSDT-2.63%ICPUSDT-1.30%ONDOUSDT-2.87%WLDUSDT-2.43%ATOMUSDT-3.41%ARBUSDT-1.04%JUPUSDT-3.82%INJUSDT-3.30%STXUSDT-3.80%FETUSDT-3.24%TIAUSDT-1.65%SEIUSDT-3.91%PYTHUSDT-1.17%IMXUSDT-3.06%WIFUSDT-4.40%GRTUSDT-3.82%OPUSDT-3.00%IOTAUSDT-3.80%POLUSDT-7.08%AXSUSDT-2.57%FARTCOINUSDT-3.67%EOSUSDT-1.86%DYDXUSDT-0.24%ORDIUSDT-0.69%GALAUSDT-4.78%NOTUSDT-0.68%RONINUSDT-2.64%NVDA-1.19%AAPL+0.67%GOOGL-2.28%MSFT-0.48%AMZN-0.82%TSM-0.83%SPCX-3.86%AVGO-1.13%META+0.20%TSLA-1.97%SKHY+7.05%MU-3.05%BRK-B+0.18%LLY+0.02%JPM+0.34%AMD+3.04%WMT-0.21%V-0.34%XOM+2.24%ASMLa-2.91%JNJ-0.76%INTC+1.69%MA-0.59%0700.HK-1.94%ORCL-0.50%1398.HK+0.79%BAC+0.45%ABBV+0.88%CSCO+0.24%CVX+1.91%COST-0.83%LRCX-1.43%KO-0.92%CAT-0.84%AMAT-0.83%0005.HK-0.78%AP2d-2.69%UNH-1.94%DELL+0.29%HSBA.L-1.34%MS-0.42%PG-2.02%GE-2.83%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX-0.96%HD-1.04%GS-0.75%0939.HK+1.66%NZDJPY-2.62%AUDJPY-1.87%CHFJPY-1.71%NZDCAD-1.45%GBPJPY-1.39%EURJPY-1.38%NZDUSD-1.37%EURNZD+1.28%USDJPY-1.28%GBPNZD+1.24%CADJPY-1.19%NZDCHF-0.95%USDZAR+0.95%USDSEK+0.88%USDNOK+0.87%AUDNZD+0.78%AUDCAD-0.72%EURZAR+0.67%USDTHB+0.61%USDMXN+0.61%AUDUSD-0.61%EURSEK+0.60%GBPZAR+0.59%EURNOK+0.59%AUDSGD-0.54%USDPLN+0.53%AUDDKK-0.52%CADCHF+0.51%EURAUD+0.50%CHFSEK+0.49%CHFNOK+0.48%GBPAUD+0.47%USDCHF+0.45%GBPTRY+0.41%NOKJPY-0.41%NZDSGD-0.38%GBPHKD+0.32%EURCHF+0.32%GBPCHF+0.30%EURHKD-0.30%GBPMXN-0.28%USDDKK+0.28%USDSGD+0.27%EURPLN+0.25%GBPCAD-0.22%EURCAD-0.20%SGDJPY+0.19%EURCNH-0.17%AUDCHF-0.17%USDILS+0.16%CHFSGD-0.12%GBPUSD-0.12%EURUSD-0.12%USDTRY+0.11%USDCNH+0.09%GBPSGD-0.09%USDCAD-0.08%PLNJPY-0.07%NZDMXN-0.06%AUDNOK+0.06%USDCOP-0.04%EURCZK-0.03%EURGBP+0.03%EURSGD-0.01%USDHKD+0.01%EURDKK0.00%XPTUSD-4.86%XAGUSD-4.32%GAGUSD-4.32%HG1-4.09%UKOIL+3.27%USOIL+3.15%COFFEE-2.45%GAUUSD-1.17%XAUUSD-1.17%SUGAR+1.15%COTTON+0.60%XNGUSD-0.29%BTCUSD-1.81%ETHUSD-2.01%USDTUSD-0.02%XRPUSD-2.77%SOLUSD-2.07%TRXUSDT-0.17%ZECUSDT-5.51%DOGEUSD-2.88%XMRUSDT-2.04%LINKUSD-1.08%XLMUSD-2.10%BCHUSDT-8.60%LTCUSD-2.09%UNIUSD-4.73%TONUSD+24.88%HBARUSDT-2.37%SUIUSD-2.75%TAOUSDT-4.55%AAVEUSD-3.25%DOTUSDT-2.63%ICPUSDT-1.30%ONDOUSDT-2.87%WLDUSDT-2.43%ATOMUSDT-3.41%ARBUSDT-1.04%JUPUSDT-3.82%INJUSDT-3.30%STXUSDT-3.80%FETUSDT-3.24%TIAUSDT-1.65%SEIUSDT-3.91%PYTHUSDT-1.17%IMXUSDT-3.06%WIFUSDT-4.40%GRTUSDT-3.82%OPUSDT-3.00%IOTAUSDT-3.80%POLUSDT-7.08%AXSUSDT-2.57%FARTCOINUSDT-3.67%EOSUSDT-1.86%DYDXUSDT-0.24%ORDIUSDT-0.69%GALAUSDT-4.78%NOTUSDT-0.68%RONINUSDT-2.64%
AP

Amylyx Pharmaceuticals, Inc. (AMLX)

NASDAQ • Healthcare

$32.4
-$1.48 (-4.4%)
Market open

Last close at September 9, 2026 at 20:00 UTC

Open$33.5
Previous Close$32.4
Day Range$32.3 - $34.35
Avg. Volume (3M)3.6M
Market Cap$3.6B
52 Week Range
$10.83$41.14
Next EarningsIn 56 daysNov 5, 2026

Metrics Over Time

Fundamentals & Financials

Revenue (TTM)
$0
Net Income (TTM)
-$152M
EPS (TTM)
-$1.41
ROA (TTM)
-57.49%
Current Ratio
12.12

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

+3.2%Q1 2026-$0.3
-8.8%Q2 2026-$0.37
-8.1%Q3 2026-$0.39
Next

Nov 5

in 56 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Miss -8.1%

Amylyx Pharmaceuticals’ earnings missed consensus in the second fiscal quarter of 2026, based on preliminary results reported August 6, 2026, with EPS of -$0.39 trailing the -$0.36 estimate by -$0.03. The company posted GAAP net income of roughly -$43.4 million, down about 5% year over year from -$41.4 million a year ago, while GAAP operating income was around -$45.7 million. Cash flow from operations was negative at roughly -$31.4 million for the quarter. Amylyx remains a clinical-stage biopharmaceutical company focused on AMX0035 in amyotrophic lateral sclerosis and other neurodegenerative conditions. For the next period, consensus calls for EPS of -$0.38 on revenue of $59,429.00.

View full earnings history

About Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals, Inc. is a NASDAQ-listed healthcare company in biotechnology that develops therapies for amyotrophic lateral sclerosis and other neurodegenerative conditions. The company operates as a clinical-stage biopharmaceutical firm, with its work centered on AMX0035, a named therapy candidate that anchors its development pipeline and research focus.

Name
Amylyx Pharmaceuticals, Inc.
CEO
Joshua Cohen
Website
amylyx.com
Industry
Healthcare
Year Founded
2013
Employees
136

Today's Snapshot

AI-generated

AMLX ended yesterday 4.4% down at 32.40. Amylyx Pharmaceuticals changed its supply agreements, altering how investors view the company.

Trading Volume

Below 10d avg (1.8M)

1.2M

vs S&P 500 Today

Strong Underperformance

-3.89%

Updated: September 10, 2026 at 12:22 UTC

Technical Indicators

5 Buy2 Neutral1 Sell
AMLX at 32.40 exhibits a strong-buy technical profile supported by a pronounced trend and positive volume. ADX is well above 40, indicating strong directional strength, and OBV is strongly positive which supports the advance despite short-term moving averages sitting above the current price. Longer-term averages (50/100/200) lie well below the market, underscoring sustained upside breadth, while MACD and other momentum measures are constructive. Volatility is elevated by a larger ATR percentage but does not negate the underlying trend. Technical takeaway: Strong Buy — strong trend and supportive volume outweigh short-term pullback signals.
All signals
  • EMA (5 indicators)$18.81 - $33.85
    Buy
  • RSI (14)56.03
    Neutral
  • Stochastic %K (14, 3, 3)19.53
    Buy
  • MACD Level (12, 26)2.75
    Neutral

Peers & Related Assets

RLAYRelay Therapeutics, Inc.
$18.66-2.4%
PGENPrecigen, Inc.
$6.8-1.0%
SNDXSyndax Pharmaceuticals, Inc.
$19.84-0.5%
INBXInhibrx Biosciences Inc.
$112.86-1.3%
ORICORIC Pharmaceuticals, Inc.
$12.5-0.9%
SANASana Biotechnology, Inc.
$3.17-8.1%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.